These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12234993)

  • 1. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
    Mellinghoff IK; Tran C; Sawyers CL
    Cancer Res; 2002 Sep; 62(18):5254-9. PubMed ID: 12234993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
    Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
    Craft N; Shostak Y; Carey M; Sawyers CL
    Nat Med; 1999 Mar; 5(3):280-5. PubMed ID: 10086382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
    Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
    Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.
    Mendoza N; Phillips GL; Silva J; Schwall R; Wickramasinghe D
    Cancer Res; 2002 Oct; 62(19):5485-8. PubMed ID: 12359757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.
    Meng TC; Lee MS; Lin MF
    Oncogene; 2000 May; 19(22):2664-77. PubMed ID: 10851066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
    Tørring N; Dagnaes-Hansen F; Sørensen BS; Nexø E; Hynes NE
    Prostate; 2003 Jul; 56(2):142-9. PubMed ID: 12746839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
    Brandt R; Wong AM; Hynes NE
    Oncogene; 2001 Sep; 20(39):5459-65. PubMed ID: 11571643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.
    Veeramani S; Yuan TC; Chen SJ; Lin FF; Petersen JE; Shaheduzzaman S; Srivastava S; MacDonald RG; Lin MF
    Endocr Relat Cancer; 2005 Dec; 12(4):805-22. PubMed ID: 16322323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
    Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.